FiberSense CGM System Achieves CE Mark for Market Launch
BASEL, Switzerland, June 17, 2026 FiberSense AG has announced that its innovative FiberSense Continuous Glucose Monitoring (CGM) System has...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
BASEL, Switzerland, June 17, 2026 FiberSense AG has announced that its innovative FiberSense Continuous Glucose Monitoring (CGM) System has...
CARLSBAD, Calif., June 16, 2026 Protillion Biosciences has announced a significant multi-target drug discovery collaboration and license agreement with...
September 22, 2025 – Brussels, Belgium – AstraZeneca and Amgen announced that the European Medicines Agency’s (EMA) Committee for...
